Background: Upper airway side effects are common during nasal continuous positive airway pressure (nCPAP) treatment and may affect the use of nCPAP. Objectives: It was our aim to evaluate the prevalence of upper airway symptoms in obstructive sleep apnea syndrome (OSAS) patients before and during nCPAP treatment and to assess the possible association between the symptoms and long-term adherence to the treatment. Methods: We examined 385 consecutive OSAS patients (79% men, mean age ± SD 52 ± 10 years and apnea-hypopnea index 33 ± 23) by means of a prospective questionnaire-based survey. The patients filled in questionnaires about upper airway symptoms before starting nCPAP and after 2 months of treatment. Results: Upper airway symptoms were common before starting nCPAP: 61% of the patients reported dryness of mouth, 54% dryness of throat, 52% nasal stuffiness, 51% dryness of nose, 30% sneezing, 24% mucus in throat, 17% rhinorrhea, and 6% nose bleeds daily or almost daily. In CPAP users there was a significant decline in the number of patients with frequent mouth (37%), throat (34%), nose (28%) dryness and nasal stuffiness (24%). There was no difference in upper airway symptoms before nCPAP treatment between those who continued the treatment after 1 year and those who terminated the treatment. Conclusions: The most common upper airway symptoms in patients with untreated OSAS seem to be associated with mucosal dryness. These symptoms improved during nCPAP treatment probably due to the change in breathing pattern. The occurrence of upper airway symptoms before nCPAP start did not predict long-term adherence to the treatment.

Keywords:
Continuous positive airway pressure, Upper airway symptoms, Obstructive sleep apnea syndrome
1.
Giles TL, Lasserson TJ, Smith BH, White J, Wright J, Cates CJ: Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2006;3:CD001106.
2.
Kakkar RK, Berry RB: Positive airway pressure treatment for obstructive sleep apnea. Chest 2007;132:1057–1072.
3.
McDaid C, Duree KH, Griffin SC, Weatherly HL, Stradling JR, Davies RJ, Sculpher MJ, Westwood ME: A systematic review of continuous positive airway pressure for obstructive sleep apnoea-hypopnoea syndrome. Sleep Med Rev 2009;13:427–436.
4.
Brander PE, Soirinsuo M, Lohela P: Nasopharyngeal symptoms in patients with obstructive sleep apnea syndrome. Effect of nasal CPAP treatment. Respiration 1999;66:128–135.
5.
Lojander J, Brander PE, Ammala K: Nasopharyngeal symptoms and nasal continuous positive airway pressure therapy in obstructive sleep apnoea syndrome. Acta Otolaryngol 1999;119:497–502.
6.
Pepin JL, Leger P, Veale D, Langevin B, Robert D, Levy P: Side effects of nasal continuous positive airway pressure in sleep apnea syndrome. Study of 193 patients in two French sleep centers. Chest 1995;107:375–381.
7.
Baltzan MA, Elkholi O, Wolkove N: Evidence of interrelated side effects with reduced compliance in patients treated with nasal continuous positive airway pressure. Sleep Med 2009;10:198–205.
8.
Kiely JL, Nolan P, McNicholas WT: Intranasal corticosteroid therapy for obstructive sleep apnoea in patients with co-existing rhinitis. Thorax 2004;59:50–55.
9.
Ryan S, Doherty LS, Nolan GM, McNicholas WT: Effects of heated humidification and topical steroids on compliance, nasal symptoms, and quality of life in patients with obstructive sleep apnea syndrome using nasal continuous positive airway pressure. J Clin Sleep Med 2009;5:422–427.
10.
Gordon P, Sanders MH: Sleep.7: positive airway pressure therapy for obstructive sleep apnoea/hypopnoea syndrome. Thorax 2005;60:68–75.
11.
Mador MJ, Krauza M, Pervez A, Pierce D, Braun M: Effect of heated humidification on compliance and quality of life in patients with sleep apnea using nasal continuous positive airway pressure. Chest 2005;128:2151–2158.
12.
Series F, St Pierre S, Carrier G: Effects of surgical correction of nasal obstruction in the treatment of obstructive sleep apnea. Am Rev Respir Dis 1992;146:1261–1265.
13.
Chandrashekariah R, Shaman Z, Auckley D: Impact of upper airway surgery on CPAP compliance in difficult-to-manage obstructive sleep apnea. Arch Otolaryngol Head Neck Surg 2008;134:926–930.
14.
Franklin KA, Rehnqvist N, Axelsson S: Obstructive sleep apnea syndrome – diagnosis and treatment. A systematic literature review from SBU. Lakartidningen 2007;104:2878–2881.
15.
Dingli K, Coleman EL, Vennelle M, Finch SP, Wraith PK, Mackay TW, Douglas NJ: Evaluation of a portable device for diagnosing the sleep apnoea/hypopnoea syndrome. Eur Respir J 2003;21:253–259.
16.
Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 1999;22:667–689.
17.
Johns MW: A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540–545.
18.
Brander PE, Lehto JT, Lindroth AM, Lahtinen TS: Nasopharyngeal symptoms do not increase during nasal CPAP treatment. Eur Respir J 2004;24(suppl 48):568S.
19.
Deegan PC, McNicholas WT: Pathophysiology of obstructive sleep apnoea. Eur Respir J 1995;8:1161–1178.
20.
Rappai M, Collop N, Kemp S, deShazo R: The nose and sleep-disordered breathing: what we know and what we do not know. Chest 2003;124:2309–2323.
21.
Young T, Finn L, Palta M: Chronic nasal congestion at night is a risk factor for snoring in a population-based cohort study. Arch Intern Med 2001;161:1514–1519.
22.
Young T, Finn L, Kim H: Nasal obstruction as a risk factor for sleep-disordered breathing. The University of Wisconsin Sleep and Respiratory Research Group. J Allergy Clin Immunol 1997;99:S757–S762.
23.
Lofaso F, Coste A, d’Ortho MP, Zerah-Lancner F, Delclaux C, Goldenberg F, Harf A: Nasal obstruction as a risk factor for sleep apnoea syndrome. Eur Respir J 2000;16:639–643.
24.
Huizing EH, de Groot JAM (eds): Functional Reconstructive Nasal Surgery. Stuttgart, Thieme, 2002.
25.
Fitzpatrick MF, McLean H, Urton AM, Tan A, O’Donnell D, Driver HS: Effect of nasal or oral breathing route on upper airway resistance during sleep. Eur Respir J 2003;22:827–832.
26.
Ruhle KH, Nilius G: Mouth breathing in obstructive sleep apnea prior to and during nasal continuous positive airway pressure. Respiration 2008;76:40–45.
27.
Massie CA, Hart RW, Peralez K, Richards GN: Effects of humidification on nasal symptoms and compliance in sleep apnea patients using continuous positive airway pressure. Chest 1999;116:403–408.
28.
Kushida CA, Littner MR, Hirshkowitz M, Morgenthaler TI, Alessi CA, Bailey D, Boehlecke B, Brown TM, Coleman J Jr, Friedman L, Kapen S, Kapur VK, Kramer M, Lee-Chiong T, Owens J, Pancer JP, Swick TJ, Wise MS, American Academy of Sleep Medicine: Practice parameters for the use of continuous and bilevel positive airway pressure devices to treat adult patients with sleep-related breathing disorders. Sleep 2006;29:375–380.
29.
Farmer SE, Quine SM, Eccles R: Efficacy of inferior turbinate coblation for treatment of nasal obstruction. J Laryngol Otol 2009;123:309–314.
30.
Garcia GJ, Bailie N, Martins DA, Kimbell JS: Atrophic rhinitis: a CFD study of air conditioning in the nasal cavity. J Appl Physiol 2007;103:1082–1092.
31.
Bachour A, Maasilta P: Mouth breathing compromises adherence to nasal continuous positive airway pressure therapy. Chest 2004;126:1248–1254.
32.
Engleman HM, Wild MR: Improving CPAP use by patients with the sleep apnoea/hypopnoea syndrome (SAHS). Sleep Med Rev 2003;7:81–99.
33.
Gay P, Weaver T, Loube D, Iber C, Positive Airway Pressure Task Force, Standards of Practice Committee, American Academy of Sleep Medicine: Evaluation of positive airway pressure treatment for sleep related breathing disorders in adults. Sleep 2006;29:381–401.
34.
Kribbs NB, Pack AI, Kline LR, Smith PL, Schwartz AR, Schubert NM, Redline S, Henry JN, Getsy JE, Dinges DF: Objective measurement of patterns of nasal CPAP use by patients with obstructive sleep apnea. Am Rev Respir Dis 1993;147:887–895.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.